Cancer Educators Slide Library: Existing and Emerging Biomarkers and Targeted Therapy for Non-Small Cell Lung Cancer


Cancer Educators Slide Library: Existing and Emerging Biomarkers and Targeted Therapy for Non-Small Cell Lung Cancer

  • Video and Slide Presentations
    The VEGF and MET Pathways as Therapeutic Targets in NSCLC — Part 1: Biology and Clinical Considerations in Anti-Angiogenic Treatment
    John Heymach, MD, PhD
    EML4-ALK: Oncogene Addiction Meets Personalized Medicine
    Thomas J Lynch Jr, MD
    EGFR Mutation: Clinical Evidence and Resistance to TKIs
    Tony SK Mok, MD
    Read Dr Love’s original email
    (from October 21, 2011)
    The VEGF and MET Pathways as Therapeutic Targets in NSCLC — Part 2: Other Biologic Targets and Agents
    John Heymach, MD, PhD
    Acquired Resistance to EGFR TKIs: What Is It and How Do We Treat?
    Vincent A Miller, MD
    Personalized Therapeutic Approaches for NSCLC Case Discussions
    Roman Perez-Soler, MD (Course Director)
    Read Dr Love’s original email featuring Dr Perez-Soler
    (from October 25, 2011)

    Since these video presentations were completed, crizotinib was granted approval by the US Food and Drug Administration for the treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.